Showing results (91-100 of 161) with videos related to
Sort By:
Pageof 17
Journal of Experimental & Clinical Cancer Research : CR|June 15, 2019
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid culturesCarminia Maria Della Corte, Giusi Barra, Vincenza Ciaramella, et al.Cancers|July 9, 2022
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCREmilio Francesco Giunta, Vincenzo De Falco, Pietro Paolo Vitiello, et al.Diagnostics (Basel, Switzerland)|November 27, 2025
Delta-Radiomics Biomarker in Colorectal Cancer Liver Metastases Treated with Cetuximab Plus Avelumab (CAVE Trial)Valerio Nardone, Vittorio Patanè, Luca Marinelli, et al.Oncotarget|October 6, 2017
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancerValentina Belli, Vincenzo Sforza, Claudia Cardone, et al.Oncotarget|December 18, 2015
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cellsCarminia Maria Della Corte, Vincenza Ciaramella, Concetta Di Mauro, et al.The Oncologist|May 23, 2022
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 PandemicStefania Napolitano, Vincenza Caputo, Anna Ventriglia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2012
Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788José Baselga, Alain C Mita, Patrick Schöffski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 13, 2018
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor ModelsCarminia Maria Della Corte, Vincenza Ciaramella, Claudia Cardone, et al.Journal of Experimental & Clinical Cancer Research : CR|January 30, 2019
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell linesPietro Paolo Vitiello, Claudia Cardone, Giulia Martini, et al.Cancers|April 13, 2023
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical TrialsDavide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, et al.Pageof 17